Delving into the Latest Updates on QR060127 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

TRPC5

Mechanism

TRPC5 inhibitors(Short transient receptor potential channel 5 inhibitors)

Therapeutic Areas

Nervous System DiseasesRespiratory Diseases

Active Indication

Chronic PainCoughInflammatory pain

Inactive Indication-

Originator Organization

Wuhan Createrna Science and Technology Co.,Ltd.

Active Organization

Wuhan Createrna Science and Technology Co.,Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价健康受试者单次口服QR060127胶囊的安全性和耐受性；次要目的：评价健康受试者单次口服QR060127胶囊的药代动力学特征；探索性目的：探索健康受试者单次口服QR060127胶囊的代谢产物；探索健康受试者单次口服QR060127胶囊后的PD特征

[Translation]

Primary purpose: To evaluate the safety and tolerability of a single oral administration of QR060127 capsules in healthy subjects; Secondary purpose: To evaluate the pharmacokinetic characteristics of a single oral administration of QR060127 capsules in healthy subjects; Exploratory purpose: To explore the metabolites of a single oral administration of QR060127 capsules in healthy subjects; To explore the PD characteristics of a single oral administration of QR060127 capsules in healthy subjects

Start Date-

Sponsor / Collaborator

Wuhan Createrna Science and Technology Co.,Ltd.

ChiCTR2200061875 / SuspendedPhase 1IIT

A randomized, double-blind, placebo-controlled, dose-escalation phase I clinical study evaluating the safety, tolerability and pharmacokinetic profiles of single-dose QR060127 capsule in healthy subjects

Start Date05 Jul 2022

Sponsor / Collaborator

The Second Affiliated Hospital of Anhui Medical University

100 Clinical Results associated with QR060127

Login to view more data

100 Translational Medicine associated with QR060127

Login to view more data

100 Patents (Medical) associated with QR060127

Login to view more data

100 Deals associated with QR060127

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Pain	Phase 1	CN	Wuhan Createrna Science and Technology Co.,Ltd.	23 Jun 2022
Cough	Phase 1	-	Wuhan Createrna Science and Technology Co.,Ltd.	-
Inflammatory pain	IND Approval	CN	Wuhan Createrna Science and Technology Co.,Ltd.	16 May 2022